Page 222 - 2020_02-Haematologica-web

F. Diop et al.
Non-canonical NF-κB activation by BIRC3 mutations bypasses the block of BTK by ibrutinib. Consistently, NF- κB activation and cell survival are unaffected by ibrutinib in both CLL cells (our study) and mantle cell lymphoma cells.14 If this preclinical evidence is validated in ibrutinib- treated patients, BIRC3 mutations may also translate into a biomarker for informing selection of novel agents.
Acknowledgments
This work was supported by: Molecular bases of disease dis- semination in lymphoid malignancies to optimize curative thera- peutic strategies, (5 x 1000 n. 21198), Associazione Italiana per la Ricerca sul Cancro Foundation, Milan, Italy (grants to GG and RF) and Progetti di Rilevante Interesse Nazionale (PRIN),
(2015ZMRFEA), Rome, Italy; partially funded by the AGING Project – Department of Excellence – DIMET, Università del Piemonte Orientale, Novara, Italy; partially funded by Novara AIL ONLUS, Novara, Italy; Associazione Italiana per la Ricerca sul Cancro (AIRC IG-17314); Swiss Cancer League, ID HSR- 4660-11-2018, Bern, Switzerland; Research Advisory Board of the Ente Ospedaliero Cantonale, Bellinzona, Switzerland; European Research Council (ERC) Consolidator grant CLL- CLONE ID: 772051; grant n. 320030_169670/1 Swiss National Science Foundation, Berne, Switzerland; Fondazione Fidinam, Lugano, Switzerland; Nelia & Amadeo Barletta Foundation, Lausanne, Switzerland; Fond’Action, Lausanne, Switzerland; Translational Research Program, grant n. 6594-20, The Leukemia & Lymphoma Society, New York, USA.
References
1. Mansouri L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Rosenquist R. NF-κB acti- vation in chronic lymphocytic leukemia: a point of convergence of external triggers and intrinsic lesions. Semin Cancer Biol. 2016; 39:40-48
2. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280-288.
11. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and ritux- imab treatment achieves long-term disease- free survival in IGHV-mutated chronic lym- phocytic leukemia. Blood. 2016;127(3):303- 309.
12. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
13. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludara- bine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12):2854-2862.
14. Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling iden- tifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nature Medicine. 2014;20(1):87-92.
15. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
16. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247- 3254.
17. Grossmann V, Kohlmann A, Schnittger A, et al. Recurrent ATM and BIRC3 mutations in patients with chronic lymphocytic leukemia (CLL) and deletion 11q22-q23. Blood. 2012;120(21):1771.
18. Rose-Zerilli MJ, Forster J, Parker H, et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica. 2014;99(4):736-742.
19. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in
chronic lymphocytic leukemia. Leukemia.
2015;29(2):329-336.
20. Nadeu F, Delgado J, Royo C, et al. Clinical
impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122-2130.
21. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131(4):682-693.
22. Jost PJ, Ruland J. Aberrant NF-kappaB signal- ing in lymphoma: mechanisms, conse- quences, and therapeutic implications. Blood. 2007;109(7):2700-2707.
23. Raponi S, Del Giudice I, Ilari C, et al. Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identi- fies a subgroup with very aggressive disease. Br J Haematol. 2019;185(1):156-159.
24. Hewamana S, Lin TT, Jenkins C, et al, The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res. 2008;14(24):8102-8111.
25. Hewamana S, Alghazal S, Lin TT, et al. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progres- sion in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111:4681-4689.
26. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 1996;274:782-784.
27. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
28. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol. 1999;19:3485-3495.
29. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev. 2005;5:297-309.
3. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011;12(8):695-708.
4. Sun SC. The noncanonical NF-κB pathway. Immunol Rev. 2012;246(1):125-140.
5. Asslaber D, Wacht N, Leisch M, Qi Y, et al. BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-κB nuclear translocation. Clin Cancer Res. 2019;25(6):1901-1912.
6. Puente XS, Beà S, Valdés-Mas R, et al. Non- coding recurrent mutations in chronic lym- phocytic leukaemia. Nature. 2015;526 (7574):519-524.
7. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolu- tion in progression and relapse. Nature. 2015;526(7574):525-530.
8. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis, indications for treatment, response assessment and sup- portive management of chronic lymphocytic leukemia. Blood. 2018;131(25):2745-2760.
9. Gaidano G, Rossi D. The mutational land- scape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017;2017(1):329-337.
10. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remis- sion after first-line fludarabine-cyclophos- phamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921-1924.
456
haematologica | 2020; 105(2)